Selected article for: "antibody response and protective vaccine"
Author: Choi, Kang-Seuk
Title: Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines
  • Document date: 2017_7_26
    • ID: vk59ghjm_31
    Snippet: ILTV, a herpesvirus that infects birds, causes respiratory disease in chickens. Currently available live attenuated ILTV vaccines are effective, but there are concerns about safety in chickens because of the risks of virulence acquirement and latent infections during bird to bird transmission [58, 59] . Bivalent NDV-vectored vaccines against ILTV have been developed to overcome side effects associated with the live ILTV vaccine. Kanabagatte Basav.....
    Document: ILTV, a herpesvirus that infects birds, causes respiratory disease in chickens. Currently available live attenuated ILTV vaccines are effective, but there are concerns about safety in chickens because of the risks of virulence acquirement and latent infections during bird to bird transmission [58, 59] . Bivalent NDV-vectored vaccines against ILTV have been developed to overcome side effects associated with the live ILTV vaccine. Kanabagatte Basavarajappa et al. [54] developed a NDV-vectored ILTV vaccine (rNDV gD) expressing glycoprotein D (gD) of ILTV. The protective efficacy of the rNDV gD vaccine against challenge with virulent ILTV and virulent NDV was then evaluated in SPF chickens. Immunizing chickens with rNDV gD (10 6 TCID50/dose) via the oro-nasal route induced a strong antibody response and provided a high level of protection against subsequent challenge with virulent IL-TV and NDV, indicating that rNDV gD has potential as a bivalent vaccine.

    Search related documents:
    Co phrase search for related documents
    • protective efficacy and strong antibody response: 1, 2
    • protective efficacy and subsequent challenge: 1, 2
    • respiratory disease and rNDV gD vaccine: 1
    • respiratory disease and SPF chicken: 1
    • respiratory disease and strong antibody response: 1, 2, 3, 4
    • respiratory disease and subsequent challenge: 1, 2, 3, 4, 5
    • strong antibody response and subsequent challenge: 1